首页> 外文期刊>Theranostics >ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo- and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a Single Light Source
【24h】

ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo- and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a Single Light Source

机译:ROS响应线粒体靶向混合的纳米粒子:肺癌的化学和光动力协同疗法与单一光源照射后按需药物释放。

获取原文
           

摘要

Mitochondria in cancer cells maintain a more negative membrane potential than normal cells. Mitochondria are the primary source of cellular reactive oxygen species (ROS), which are necessary for photodynamic therapy. Thus, the strategy of targeting mitochondria can maximize the photodynamic therapeutic efficiency for cancer. Here we report, for the first time, synthesis of a new mitochondria-targeting drug delivery system, ZnPc/CPT-TPPNPs. To synthesize this novel compound, polyethylene glycol was functionalized with thioketal linker-modified camptothecin (TL-CPT) and triphenylphosphonium to form the block copolymer, TL-CPT-PEG1K-TPP. The ZnPc/CPT-TPPNPs was constructed for delivery of the photosensitizer Zinc phthalocyanine (ZnPc) by blending the block copolymer TL-CPT-PEG1K-TPP with 1, 2-distearoyl- sn -glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] (DSPE-PEG).Triphenylphosphine can accumulate selectively several hundred-fold within mitochondria. The thioketal linker is ROS-responsive and CPT can be released upon ROS cleavage. We also show that the ZnPc loaded in ZnPc/CPT-TPPNPs absorbed the 633 nm laser to produce ROS, which could be utilized both in photodynamic therapy and to cleave the thioketal linker thereby releasing camptothecin for chemotherapy. Thus, the mitochondria-targeting nanoparticles could elevate photodynamic therapeutic efficacy. Our results showed that surface modification of the nanoparticles with triphenylphosphine cations facilitated efficient subcellular delivery of the photosensitizer to mitochondria. The nanoparticles had a good ROS-responsive effect to release CPT, which could transfer to the nucleus and interfere with DNA replication as a topoisomeraseⅠinhibitor. Thus, the blended nanoparticles provide a new promising approach as a mitochondria-targeting ROS-activated chemo- and photodynamic therapy with a single light source for lung cancer.
机译:癌细胞中的线粒体比正常细胞保持更大的负膜电位。线粒体是细胞光化学疗法所必需的细胞活性氧(ROS)的主要来源。因此,靶向线粒体的策略可使癌症的光动力治疗效率最大化。在这里,我们首次报告了靶向线粒体的新药物递送系统ZnPc / CPT-TPPNPs的合成。为了合成这种新型化合物,将聚乙二醇用硫酮连接基修饰的喜树碱(TL-CPT)和三苯基phosph官能化,形成嵌段共聚物TL-CPT-PEG 1K -TPP。通过将嵌段共聚物TL-CPT-PEG 1K -TPP与1,2,2-二硬脂酰基-sn-glycero-3掺混来构建ZnPc / CPT-TPPNPs来递送光敏剂锌酞菁(ZnPc) -磷酸乙醇胺-N- [甲氧基(聚乙二醇)](DSPE-PEG)。三苯基膦可以选择性地在线粒体内积累数百倍。硫缩酮连接子对ROS敏感,CPT可以在ROS裂解后释放。我们还表明,加载在ZnPc / CPT-TPPNPs中的ZnPc吸收了633 nm激光以产生ROS,可将其用于光动力治疗和裂解硫缩酮连接子,从而释放喜树碱用于化学疗法。因此,线粒体靶向纳米颗粒可以提高光动力治疗功效。我们的结果表明,用三苯基膦阳离子对纳米粒子进行表面修饰有助于光敏剂有效地亚细胞递送至线粒体。纳米粒子具有良好的ROS响应释放CPT的作用,可以作为拓扑异构酶Ⅰ抑制剂转移到细胞核并干扰DNA的复制。因此,掺合的纳米颗粒提供了一种新的有前途的方法,作为针对肺癌的单一光源的靶向线粒体的ROS激活的化学和光动力疗法。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号